20 November 2018
By Dr Wendy Winnall - PCFA Research Team
Active surveillance is a common management for low-risk, localised prostate cancer in Australia. The aim is to avoid or delay treatment until it becomes necessary. Unfortunately, guidelines vary greatly for who should go on active surveillance and what tests they should have. The Movember Foundation's GAP3 program aims to create a global consensus on selection and monitoring of men with low-risk prostate cancer. As part of this project, the GAP3 research team have recently published a study examining the reasons why men drop out of active surveillance.
To read the full article just log into the PCFA Online Community.
If you're not already a member, it is free and easy to join.
